

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022065 A1

- (51) International Patent Classification⁷: **A61K 31/56**
- (21) International Application Number:
PCT/NL2003/000621
- (22) International Filing Date:
5 September 2003 (05.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02078643.0 5 September 2002 (05.09.2002) EP
- (71) Applicant (*for all designated States except US*): **PAN-TARHEI BIOSCIENCE B.V.** [NL/NL]; P.O. Box 464, NL-3700 AL Zeist (NL).
- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): **BUNSCHOTEN, Evert, Johannes** [NL/NL]; Plantsoen 16, NL-5384 EV Heesch (NL). **COELINGH BENNINK, Herman, Jan, Tijmen** [NL/NL]; Melvill van Carnbeelaan 38, NL-3971 BE Driebergen (NL). **VAN DER LINDEN, René, Frank** [NL/NL]; Amersfoortseweg 4, NL-3951 LB Maarn (NL).
- (74) Agent: **VAN WESTENBRUGGE, Andries et al.**; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES

(57) Abstract: The present invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the present invention is concerned with such pharmaceutical dosage units containing at least 10 µg of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term "15-hydroxytestosterones" encompasses both 15α-hydroxytestosterone (15α, 17β-dihydroxy-4-androsten-3-one) and 15β-hydroxytestosterone (15β, 17β-dihydroxy-4-androsten-3-one). Similarly, the term "16-hydroxytestosterones" encompasses both 16α-hydroxytestosterone (16α, 17β-dihydroxy-4-androsten-3-one) and 16β-hydroxytestosterone (16β, 17β-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.

PHARMACEUTICAL APPLICATION OF 15- OR 16- SUBSTITUTED TESTOSTERONE ANALOGUES

5 TECHNICAL FIELD

The present invention is in the field of steroid chemistry. More particularly it relates to pharmaceutical dosage units containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. The
10 testosterone analogues of the invention possess androgenic activity.

BACKGROUND OF THE INVENTION

15 British patent GB-B 774,064 is concerned with a process for the production of 15-substituted testosterone, particularly 15-hydroxytestosterone. Therapeutic applications of these substances are nowhere mentioned in the patent.

French patent application FR-A 2 035 786 describes veterinary applications of 16α - α -D-glucosiden of $16\alpha,17$ dihydroxysteroids. It is stated that these steroids can be used as
20 estrogens to prevent ovulation in animals such as rodents, dogs, cow and sheep. Claim 3 mentions the glucoside of 16α -hydroxytestosterone. Only parenteral administration is mentioned in the French application.

At present, the main therapeutic application of androgenic steroids is in the treatment of hypogonadal males. Methods of treating androgen deficiency comprising the
25 administration of androgens, such as testosterone, dihydrotestosterone, dehydroepiandrosterone and various esters of testosterone, or derivatives and analogues such as mesterolone are known in the art.

Three types of androgen deficiency in males are usually distinguished, i.e. primary androgen deficiency (testicular insufficiency), secondary androgen deficiency (hypothalamo-
30 hypophyseal insufficiency) and androgen deficiency in ageing males (ADAM), also known as "male menopause" or "andropause".

As regards the long-term administration of androgens to males, a distinction can be made between therapy and supplementation. Therapy typically requires relatively high doses

that are usually similar to the rate of production of endogenous androgens. Supplementation on the other hand is suitably done with dosages that are below the rate of production of endogenous androgens (i.e. testosterone, dihydrotestosterone and dehydroepiandrosterone).

Because of concerns about undesirable side effects, androgens are only used sparingly in both therapy and hormone supplementation. Indeed, androgens are normally only used for therapy in human males when primary or secondary androgen deficiency has been diagnosed.

Only a few androgens, e.g. dehydroepiandrosterone (DHEA) and 17 α -alkylated derivatives of testosterone, are suitable for oral administration because, unlike testosterone, they are largely resistant to hepatic metabolism. However, disadvantages of oral administration are associated with the bad absorption of these androgens and the relatively high effect they exert on the liver and particular the liver metabolism (Bhasin et al. (1997) J. Clin. Endocr. Metab. 82:3-8). This is why, in existing protocols, androgens are generally administered in the form of 2-3 weekly depot injections or implants.

It has also been suggested in the prior art to use a combination of a progestogen and an androgen in a method of male contraception. In such a method the progestogen is administered in a sufficiently high amount to halt spermatogenesis - leading to azoospermia - and the androgen is co-administered to prevent androgen deficiency which would otherwise result from the administration of the progestogen. Because of concerns about reliability and possible side-effects of the androgenic component, particularly when administered orally, male contraceptive have not yet made it beyond the experimental stage.

Other therapeutic uses of androgens that have been proposed in the prior art include treatment of the wasting syndrome and retro-viral drug induced lipodystrophia in HIV infected individuals, enhancement of recovery of critically ill catabolic individuals, treatment of benign gynaecological disorders hormonal contraception in females, delayed puberty, female-to-male conversion.

As will be apparent from the above, there is an unmet need for androgens that (i) can be used effectively in the above mentioned therapeutic methods without causing undesirable side-effects, (ii) produce a very consistent, i.e. predictable, impact and/or (iii) may be administered in a convenient manner, especially orally.

SUMMARY OF THE INVENTION

The inventors have unexpectedly discovered that steroids which have not been used in therapeutic applications, i.e. 15-hydroxy or 16-hydroxy substituted testosterone analogues, meet the aforementioned requirements.

Surprisingly, it was found that the hydroxytestosterone analogues according to the present invention combine adequate androgenic potency with acceptable oral bioavailability and minimum impact on liver metabolism. Consequently, the present androgens are particularly suited for any therapeutic applications for which androgens have been employed or recommended. The present hydroxytestosterone analogues may also be delivered effectively, particularly in relatively low dosages such as those typically required by females, by transmucosal or transdermal administration.

Another advantage of the hydroxytestosterone analogues according to the invention is their predictable and consistent therapeutic impact, which is believed to be related to the efficiency of uptake, their low hepatic effect and/or their low affinity for sex hormone binding globulin (SHBG). In contrast, the therapeutic effect of known androgens that are sometimes administered orally, notably DHEA or 17 α -alkylated derivatives of testosterone, is very dependent on an individual's physiology and even his/her diet. Consequently, these androgens are usually applied in relatively high dosages in order to ensure that the minimum effective dosage is achieved in each individual. Naturally such high dosages have the disadvantage that they lead to relative overdosing in some individuals, which in turn is likely to produce pronounced side effects.

DETAILED DESCRIPTION OF THE INVENTION

Accordingly, one aspect of the invention relates to a pharmaceutical dosage unit for oral, transmucosal or transdermal administration containing at least 10 μ g of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient.

The term "15-hydroxytestosterones" encompasses both 15 α -hydroxytestosterone (15 α ,17 β -dihydroxy-4-androsten-3-one) and 15 β -hydroxytestosterone (15 β ,17 β -dihydroxy-4-androsten-3-one). Similarly, the term "16-hydroxytestosterones" encompasses both 16 α -

hydroxytestosterone hydroxytestosterone ($16\alpha,17\beta$ -dihydroxy-4-androsten-3-one) and 16β -hydroxytestosterone ($16\beta,17\beta$ -dihydroxy-4-androsten-3-one).

The term "precursor" as used throughout this document refers to substances which are converted into one of the hydroxytestosterones of the invention following the administration of said precursor to a human subject.

Preferred precursors of the androgenic steroids according to the present invention are derivatives of the present hydroxytestosterones wherein the hydrogen atom of at least one hydroxylgroup has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue.

It has been shown that the hydroxytestosterones of the present invention occur in mammals, which means that they offer the important advantage that they can be labelled as natural (Yamazaki et al. Arch Biochem Biophys 1997 Oct 1;346(1):161-9). In addition, as can be derived from the aforementioned article, both 15α -hydroxytestosterone, 15β -hydroxytestosterone and 16β -hydroxytestosterone occur in the human body, which means that *prima facie* the risk of undesired side-effects is lower than is the case for synthetic androgens or natural androgens that are not found in the human body. Thus, in a particularly preferred embodiment of the present invention, the androgenic steroid is selected from the group consisting of 15α -hydroxytestosterone, 15β -hydroxytestosterone, 16β -hydroxytestosterone, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors. Even more preferably, the androgenic steroid is selected from the group consisting of 15α -hydroxytestosterone, 15β -hydroxytestosterone precursors thereof and mixtures of these hydroxytestosterones and/or their precursors.

The present oral dosage units may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such units may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents. Said dosage units may suitably contain a non-toxic pharmaceutically acceptable excipient. In case of e.g. tablets, these excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatine or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and

thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Examples of dosage unit forms that may be administered by oral route include tablets, soft gelatine capsules, including solutions used in soft gelatine capsules, aqueous or oil suspensions, emulsions, pills, lozenges, troches, syrups, elixirs and the like. Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the steroid component is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil. In a particularly preferred embodiment, the oral dosage units according to the present invention are provided in the form of solid or semi-solid dosage units, especially in the form of tablets, capsules, cachets, pellets, pills, powders or granules.

Aqueous suspensions according to the invention contain the steroids in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Ophthalmic formulations, as is known in the art, will be adjusted for osmotic pressure.

Oil suspensions may be formulated by suspending the steroid component in a vegetable oil, such as arachide oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water may be formulated from the steroid component in a mixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical dosage unit of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachide oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavouring or a colouring agent.

The steroids of this invention may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These dosage units can be prepared by mixing the steroid with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

The present dosage unit preferably contains at least 20 μg , more preferably at least 40 μg and most preferably at least 60 μg of the androgenic steroid. In case the dosage unit is meant to provide a sustained release of the androgenic steroid, e.g. in case of a transdermal patch, the amount of androgenic steroid contained in the dosage unit may be as high as 1000 mg. Preferably the amount of the androgenic steroid does not exceed 500 mg, more preferably it does not exceed 200 mg. Most preferably the amount of androgenic steroid in the dosage unit does not exceed 100 mg.

In a particularly preferred embodiment of the invention, the dosage unit is designed for oral administration. Examples of oral dosage units which may suitably be used to deliver the present steroids include tablets, capsules, cachets, pellets, pills, powders or granules.

Typically the present pharmaceutical oral dosage unit has a weight in the range of 0.1-10 grams. The amount of androgenic steroid contained in the oral dosage unit is preferably at

least 30 μg , more preferably at least 50 μg and most preferably at least 80 μg . Usually the amount of steroid contained in the oral dosage unit will not exceed 50 mg, more preferably it will not exceed 30 mg, most preferably it will not exceed 20 mg.

The hydroxytestosterone analogues of the present invention may advantageously be employed in a method of male contraception. As mentioned herein before, such a method requires the combined administration of a progestogen and an androgen. Typically the amount of progestogen included in the present dosage unit will exceed 10 μg , preferably it will exceed 30 μg . In a particularly preferred embodiment, the present dosage unit additionally contains a progestogen in an amount equivalent to between 75 and 800 μg , more preferably between 100 and 500 μg levonorgestrel.

In other applications, e.g. in female hormone replacement therapy or female contraception, it may be advantageous to administer the present hydroxytestosterone analogues in combination with an estrogen. Accordingly, the present dosage unit, in addition to the present androgenic steroid, may suitably contain an estrogen, preferably in an amount of at least 10 μg , more preferably in an amount of at least 15 μg .

Examples of progestogens that may employed in the present dosage unit as well as in the methods described herein include progesterone, levonorgestrel, norgestimate, norethisterone, dydrogesterone, drospirenone, 3-beta-hydroxydesogestrel, 3-keto desogestrel (=etonogestrel), 17-deacetyl norgestimate, 19-norprogesterone, acetoxypregnenolone, allylestrenol, anagestone, chlormadinone, cyproterone, demegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate, flurogestone acetate, gastrinon, gestodene, gestrinone, hydroxymethylprogesterone, hydroxyprogesterone, lynestrenol (=lynoestrenol), medrogestone, medroxyprogesterone, megestrol, melengestrol, nomegestrol, norethindrone (=norethisterone), norethynodrel, norgestrel (includes d-norgestrel and dl-norgestrel), norgestrienone, normethisterone, progesterone, quingestanol, (17alpha)-17-hydroxy-11-methylene-19-norpregna-4,15-diene-20-yn-3-one, tibolone, trimegestone, algestone acetophenide, nestorone, promegestone, 17-hydroxyprogesterone esters, 19-nor-17hydroxyprogesterone, 17alpha-ethinyl-testosterone, 17alpha-ethinyl-19-nor-testosterone, d-17beta-acetoxy-13beta-ethyl-17alpha-ethinyl-gon-4-en-3-one oxime, precursors of these compounds that are capable of liberating these progestogens *in vivo* when used in the present method and combinations thereof. Preferably the progestogen is selected from the group consisting of progesterone, desogestrel, etonogestrel, gestodene, dienogest, levonorgestrel, norgestimate, norethisterone, drospirenone, trimegestone, dydrogesterone, precursors of these progestogens and combinations thereof.

Examples of estrogens that may suitably be used in accordance with the present invention include ethinyl estradiol, mestranol, quinestranol, estradiol, estrone, estran, estriol, estetrol, conjugated equine estrogens, precursors thereof that are capable of releasing such an estrogen *in vivo* when used in the present method and combinations thereof. Preferably the
5 estrogen is selected from the group consisting of ethinyl estradiol, estradiol, estetrol and combinations thereof.

Preferred precursors of the androgenic steroids according to the present invention are derivatives of the present hydroxytestosterones wherein the hydrogen atom of at least one hydroxylgroup has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic
10 or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue.

Another aspect of the invention relates to a method of curatively or prophylactically treating a mammal, said method comprising oral, transmucosal or transdermal administration to said mammal of the present pharmaceutical dosage unit as described herein before. The
15 term transmucosal administration as used herein, refers to intravaginal, intra-uterine, rectal, intranasal, pulmonary, buccal and sublingual delivery, intravaginal delivery being most preferred. The present method is particularly suitable for treating humans.

Oral, rectal, intranasal, buccal and pulmonary administration are ideally suited for (at least) once daily administration. Transdermal administration is advantageously applied at
20 frequencies between once a day and once a month. Intravaginal and intra-uterine administrations are advantageously operated at administration frequencies between once weekly and once monthly.

For reasons of convenience and also to achieve high compliance rates, the present method preferably utilises administration intervals of 1 day, 1 week or 1 month. Regimens
25 that employ once daily oral administration, once weekly transdermal administration or once monthly intravaginal administration are particularly preferred. Most preferably the present method comprises at least once daily administration.

The androgenic steroid(s) of the invention are advantageously administered in an average daily amount which is at least 0.5 μg per kg of bodyweight. Preferably the average
30 daily amount is at least 1 μg per kg of bodyweight, more preferably at least 1.5 μg per kg of bodyweight. The average daily amount usually does not exceed 1.5 mg per kg of bodyweight. Preferably the average daily amount does not exceed 1 mg per kg of bodyweight, more preferably it does not exceed 0.5 mg per kg of bodyweight.

The method according to the present invention is preferably employed in a method of treating or preventing androgen deficiency (in males or females); a method of hormonal contraception (in males or females); a method of treating or preventing wasting syndrome, anti-retroviral drug induced lipodystrophia, lack of well-being or fatigue in HIV infected individuals; a method of reversing catabolic state caused by a chronic illness, surgical intervention, oncological condition, trauma and/or malnutrition; a method of treating or preventing leydig cell dysfunction and germinal epithelial damage following cytotoxic chemotherapy; a method of treating or preventing fatigue or maintaining weight, hemoglobine or neutrophil count during or subsequent to cytotoxic chemotherapy or radiotherapy; a method of treating or preventing benign gynaecological disorders; a method of improving libido (in males or females); a method of treating or preventing delayed puberty; or a method of supporting female-to-male conversion. As mentioned herein before, the administration of the present steroids is particularly advantageous when employed in a method of treating or preventing androgen deficiency, a method of hormonal contraception or a method of treating or preventing benign gynaecological disorders. It is noted that symptoms of androgen deficiency can occur in both males and females. In a particularly preferred embodiment the present is used to treat or prevent androgen deficiency or employed as a contraceptive method in males.

The aforementioned methods usually employ continuous administration of the present steroids during a period of at least 10 days, preferably of at least 20 days. In a particular preferred embodiment the present steroids are administered during a period of at least 100 days with administration-free intervals that do not exceed 10 days, preferably do not exceed 8 days.

In a preferred embodiment, the present method comprises the co-administration of a progestogen in an average daily amount of at least 0.2 μg per kg of bodyweight and/or an estrogen in an average daily amount of at least 0.2 μg per kg of bodyweight. Typically, the average daily amount of co-administered progestogen or estrogen will not exceed 1 mg per kg of bodyweight, more preferably said amount does not exceed 500 μg per kg of bodyweight, most preferably it does not exceed 300 μg per kg of bodyweight.

Yet another aspect of the invention relates to the use of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors in the preparation of an oral, transmucosal or transdermal dosage unit as described herein. In a particularly preferred embodiment, said androgenic steroid is used in the preparation of a solid or semi-

solid oral dosage unit, especially an oral dosage unit in the form of a tablet, a capsule, a cachet, a pellet, a pill, a powder or granules.

The invention is further illustrated by means of the following examples.

5

EXAMPLES

Example 1

10

An established competitive steroid binding assay was used to determine the relative binding affinity of 15α -hydroxytestosterone ($15\alpha,17\beta$ -dihydroxy-4-androsten-3-one), 15β -hydroxytestosterone ($15\beta,17\beta$ -dihydroxy-4-androsten-3-one) and 16β -hydroxytestosterone ($16\beta,17\beta$ -dihydroxy-4-androsten-3-one) to the androgen receptor (AR). Testosterone (17β -hydroxy-4-androsten-3-one) and 5α -dihydroxytestosterone (DHT, $5\alpha,17\beta$ -dihydroxy-androstan-3-one) served as controls in this assay.

15

The method employed was adapted from the scientific literature and described in detail by Chang et al (1987, J. Steroid Biochem., 27, 1-3, 123-131). Recombinant rat AR was expressed and purified from E. Coli. The *in vitro* assays involved the use of AR and [3 H]mibolerone, at a fixed concentration of 1.5 nM, as the labeled ligand. Recombinant AR was dissolved in binding buffer (50 mM Tris-Base, pH 7.5, 0.8 mM NaCl, 10% glycerol, 2 mM dithiothreitol, 1 mg/ml BSA and 2% ethanol) and duplicate aliquots were then incubated with [3 H]mibolerone at a final concentration of 1.5 nM, together with a vehicle control (1.0% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 4 h at 4 °C, the unbound ligands were removed and the amounts of [3 H]mibolerone bound to the AR was measured. The average amounts of [3 H]mibolerone bound to AR at each concentration of competitor were used to make inhibition curves. IC₅₀ values were subsequently determined by a non-linear, least squares regression analysis. Inhibition constants (K_i) were calculated using the equation of Cheng and Prusoff (Cheng et al., 1973, Biochem. Pharmacol., 22, 3099-3108), using the measured IC₅₀ of the tested compounds, the concentration of radioligand employed in the assay, and the historical values for the K_d of the radioligand, which has been established as 3 nM.

25

20

30

Mean K_i values obtained for 15α -hydroxytestosterone, 15β -hydroxytestosterone, 16β -hydroxytestosterone, testosterone and DHT from three separate experiments are shown in Table 1. For comparison of binding affinities, the K_i value of DHT (which shows the highest affinity) was arbitrarily set at 100% and used to calculate the relative affinities (Table 1). As compared to DHT and testosterone, 15α -hydroxytestosterone, 15β -hydroxytestosterone and 16β -hydroxytestosterone bind with 2 to 3 orders of magnitude less affinity to AR (Table 1).

Table 1: Experimentally determined inhibition constants (K_i) for AR binding of 15α -hydroxytestosterone, 15β -hydroxytestosterone, 16β -hydroxytestosterone, testosterone and 5α -dihydroxytestosterone (DHT). Relative binding affinities are also shown, using K_i value of DHT as 100%.

Trivial Name (Chemical Name)	AR-binding	
	K_i (nM)	Relative affinity (%)
15α -hydroxytestosterone (4-ANDROSTEN- 15α , 17β -DIOL-3-ONE)	1820	0,05
15β -hydroxytestosterone (4-ANDROSTEN- 15β , 17β -DIOL-3-ONE)	557	0,18
16β -hydroxytestosterone (4-ANDROSTEN- 16β , 17β -DIOL-3-ONE)	814	0,12
Testosterone (4-ANDROSTEN- 17β -OL-3-ONE)	2	50
5α -dihydroxytestosterone, DHT (5α -ANDROSTAN- 17β -DIOL-3-ONE)	1	100

Example 2

To determine the *in vivo* androgenic potency of 15-substituted testosterone derivatives, 15α -hydroxytestosterone ($15\alpha,17\beta$ -dihydroxy-4-androsten-3-one) and 15β -hydroxytestosterone ($15\beta,17\beta$ -dihydroxy-4-androsten-3-one) were administered orally, once daily, to immature male Wistar rats for 5 consecutive days. Testosterone (17β -hydroxy-4-androsten-3-one) and 5α -dihydroxytestosterone (DHT, $5\alpha,17\beta$ -dihydroxy-androstan-3-one), both administered orally, served as positive controls in this bioassay.

15α -hydroxytestosterone, 15β -hydroxytestosterone, testosterone and 5α -dihydroxytestosterone were dissolved in an aqueous suspension of 2% Tween 80, at final test concentrations of 3 mg/ml and 1 mg/ml. Groups of 5 immature male Wistar rats, weighing 50 ± 2 grams, received either vehicle treatment or were administered 30 or 10 mg/kg/day test substance by oral gavage in a dosing volume of 10 ml per kg for 5 consecutive days. During

the experiment, animals were housed in cages of 45 x 23 x 15 cm and maintained in a controlled temperature of 22-24 °C and humidity (60-80%) environment with 12 hours light/dark cycles. Food (lab diet, rodent diet, PMI nutrition international) and water intake was *ad libitum*.

The animals were sacrificed 24 hours after receiving the final dose and the wet weight of the seminal vesicle of each animal was recorded and average wet weight per group was calculated. Increase in average seminal vesicle wet weight relative to the average seminal vesicle wet weight of vehicle treated rats was considered indicative for *in vivo* androgenicity.

In vivo androgenicity data are shown in Table 2. Both 15 α and 15 β hydroxy-substituted analogues of testosterone induced a dose-dependent and significant increase in seminal vesicle wet weight. These *in vivo* androgenic effects were similar or equipotent to the dose-dependent effects observed for testosterone and considerably more potent than the *in vivo* androgenicity observed after oral administration of DHT, a classical androgen and the active metabolite of testosterone *in vivo* (O'Donnel et al., 1996, Endocrinology, 137, 2703-2710).

Table 2: Average increase in seminal vesicle wet weight relative to the average wet weight of vehicle (2% Tween-80) treated animals for groups of 5 immature Wistar rats, treated once daily, orally, for five consecutive days with 15 α -hydroxytestosterone, 15 β -hydroxytestosterone, testosterone or 5 α -dihydroxytestosterone (DHT). Relative androgenic potencies are also shown, using DHT as reference (100%).

Trivial Name (Chemical Name)	In vivo androgenicity		
	Oral dose mg/kg/day	Increase seminal vesicle wet weight (%)	Relative potency (%)
15 α -hydroxytestosterone (4-ANDROSTEN-15 α , 17 β -DIOL-3-ONE)	30	40	148
	10	28	560
15 β -hydroxytestosterone (4-ANDROSTEN-15 α , 17 β -DIOL-3-ONE)	30	35	130
	10	20	400
Testosterone (4-ANDROSTEN-17 β -OL-3-ONE)	30	47	174
	10	41	820
5 α -dihydroxytestosterone, DHT (5 α -ANDROSTAN-17 β -DIOL-3-ONE)	30	27	100
	10	5	100

Example 3

An established competitive steroid-binding assay (Hammond and Lahteenmaki. 1983. Clin Chem Acta 132:101-110) was used to determine the relative binding affinity of 15 α -hydroxytestosterone (15 α -OH-T), 15 β -hydroxytestosterone (15 β -OH-T), dehydroepiandrosterone (DHEA), testosterone (T) and 5 α -dihydrotestosterone (DHT) for human sex Hormone Binding Globulin (SHBG).

Human SHBG was purified from transgenic mouse serum, as described previously (Avvakumov GV et al., 2000. J Biol Chem 275: 25920-25925). The human SHBG prepared in this way was assessed to be >99% pure by polyacrylamide gel electrophoresis under denaturing conditions. Its steroid-binding characteristics are indistinguishable from SHBG in human serum (Avvakumov GV et al., 2000. J Biol Chem 275: 25920-25925). The *in vitro* assay involved the use of the purified human SHBG and [3 H]DHT as the labeled ligand. Human SHBG was treated for 30 min at room temperature with a dextran-coated charcoal (DCC) suspension in phosphate buffered saline (PBS) to remove any steroid ligand. After centrifugation (2,000 x g for 10 min) to sediment the DCC, the supernatant containing the human SHBG was diluted in PBS to a concentration of 1 nM based on its steroid binding capacity.

Duplicate aliquots (100 μ l) of this human SHBG solution were then incubated with an equal volume of [3 H]DHT at 10 nM, together with 100 μ l of PBS alone or the same amount of PBS containing increasing concentrations of unlabeled steroid ligands as competitors in polystyrene test tubes. After incubation for 1 h at room temperature the reaction mixtures were placed in an ice bath for a further 15 min. Aliquots (600 μ l) of an ice cold suspension of DCC were then added to each tube, and after a brief 2 seconds mixing, each tube was incubated in an ice bath for 10 min. The unbound ligands adsorbed to DCC were then removed by centrifugation (2,000 x g for 15 min at 4 $^{\circ}$ C), and the amounts of [3 H]labeled DHT bound to SHBG were counted in 2 ml ACS scintillation cocktail using in liquid scintillation spectrophotometer. The average amounts of [3 H] labeled DHT bound to SHBG at each concentration of competitor (B) were expressed as a percentage of the average amounts of [3 H]labeled DHT bound to SHBG in the absence of competitor (T), and were plotted against the concentration of competitor in each assay tube.




Figure 1: Competition curves showing displacement of [³H]DHT from human SHBG using 5α-dihydrotestosterone (DHT), testosterone (T), dehydroepiandrosterone (DHEA), 15α-hydroxytestosterone (15α-OH-T), 15β-hydroxytestosterone (15β-OH-T) as competitors. Results are expressed as bound (B) cpm at each competitor concentration/total (T) cpm bound in absence of competitor as a percentage.

The results of the competitive binding assays are depicted in Figure 1. The data show that 15α-OH-T and 15β-OH-T do not bind human SHBG, when compared to DHT, T or DHEA in a competitive binding assay in which [³H]DHT was used as labeled ligand. Therefore, in contrast to other androgens, the binding of 15α-OH-T or 15β-OH-T to human SHBG can be considered negligible.

CLAIMS

1. A pharmaceutical dosage unit for oral, transmucosal or transdermal administration containing at least 10 μg of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient.
2. The pharmaceutical dosage unit according to claim 1, wherein the steroid is selected from the group consisting of 15 α -hydroxytestosterone, 15 β -hydroxytestosterone, 16 β -hydroxytestosterone, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors.
3. The pharmaceutical dosage unit according to claim 2, wherein the steroid is selected from the group consisting of 15 α -hydroxytestosterone, 15 β -hydroxytestosterone, precursors thereof and mixtures of these hydroxytestosterones and/or these precursors.
4. The pharmaceutical dosage unit according to claim 3, wherein the steroid is selected from the group consisting of 15 α -hydroxytestosterone, precursors thereof and mixtures of 15 α -hydroxytestosterone and/or these precursors.
5. The pharmaceutical dosage unit according to claim 3, wherein the steroid is selected from the group consisting of 15 β -hydroxytestosterone, precursors thereof and mixtures of 15 β -hydroxytestosterone and/or these precursors.
6. The pharmaceutical dosage unit according to claim 2, wherein the steroid is selected from the group consisting of 16 β -hydroxytestosterone, precursors thereof and mixtures of 16 β -hydroxytestosterone and/or these precursors.
7. The pharmaceutical dosage unit according to any one of claims 1-6, wherein the precursors of the hydroxytestosterones are derivatives of the hydroxytestosterones wherein the hydrogen atom of at least one hydroxyl group has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms;

tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue.

8. The pharmaceutical dosage unit according to any one of claim 1-7, wherein the dosage unit is an oral dosage unit.
9. The pharmaceutical dosage unit according to claim 8, wherein the dosage unit is a tablet, a capsule, a cachet, a pellet, a pill, a powder or granules.
10. The pharmaceutical dosage unit according to any one of claims 1-9, wherein the dosage unit contains between 20 μg and 1000 mg, preferably between 40 μg and 500 mg of the androgenic steroid.
11. The pharmaceutical dosage unit according to any one of claims 1-10, wherein the dosage unit additionally contains at least 10 μg of a progestogen and/or at least 10 μg of an estrogen.
12. The pharmaceutical dosage unit according to any one of claims 1-11 for use in a method of curatively or prophylactically treating a mammal, said method comprising oral, transmucosal or transdermal administration of the dosage unit to said mammal.
13. The pharmaceutical dosage unit according to claim 12, wherein the method comprises oral administration of the dosage unit to said mammal.
14. The pharmaceutical dosage unit according to claim 12 or 13, wherein the method comprises the administration of the steroid in an average daily amount in the range of 0.5 μg to 1.5 mg per kg of bodyweight, preferably of 1 μg to 1 mg per kg of bodyweight.
15. The pharmaceutical dosage unit according to any one of claims 12-14 for use in a method of treating or preventing androgen deficiency; a method of hormonal contraception; a method of treating or preventing wasting syndrome, anti-retroviral drug induced lipodystrophia, lack of well-being or fatigue in HIV infected individuals; a method of reversing catabolic state caused by a chronic illness, surgical intervention, oncological condition, trauma and/or malnutrition; a method of treating or preventing leydig cell

dysfunction and germinal epithelial damage following cytotoxic chemotherapy; a method of treating or preventing fatigue or maintaining weight, hemoglobine or neutrophil count during or subsequent to cytotoxic chemotherapy or radiotherapy; a method of treating or preventing benign gynaecological disorders; a method of improving libido; a method of
5 treating or preventing delayed puberty; or a method of supporting female-to-male conversion.

16. Use of an androgenic steroid selected from the group consisting of 15-

hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these

10 hydroxytestosterones and/or their precursors in the preparation of an oral, transmucosal or transdermal dosage unit.

INTERNATIONAL SEARCH REPORT

PCT/NL 03/00621

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/56		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 774 064 A (UPJOHN CO) 1 May 1957 (1957-05-01) claim 2 page 1, line 19 - line 20 page 3, line 66 - line 70	1-5, 7-9, 11-15
X	FR 2 035 786 A (SQUIBB & SONS INC) 24 December 1970 (1970-12-24) claims 1, 3, 7, 8 page 1, line 38	1, 7-9, 11-15
X	WO 01 23405 A (HOLLIS EDEN PHARMACEUTICALS IN) 5 April 2001 (2001-04-05) claims 1, 2	1-9, 11-15
A	US 6 117 446 A (PLACE VIRGIL A) 12 September 2000 (2000-09-12) claims 1, 2	
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		
<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">25 November 2003</div>	Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">04/12/2003</div>	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <div style="text-align: center; font-weight: bold;">Beranová, P</div>	

INTERNATIONAL SEARCH REPORT

PCT/NL 03/00621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 00 74684 A (GEN HOSPITAL CORP ;CROWLEY WILLIAM F JR (US); MARTIN KATHRYN A (US) 14 December 2000 (2000-12-14) claims 1,6</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

PCT/NL 03/00621

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 - 16 relate to an extremely large number of possible compounds ("precursors thereof" and "mixtures of these precursors"). In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely compositions comprising 15- or 16-hydroxytestosterones and their use in therapy.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/NL 03/00621

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 774064	A	01-05-1957	NONE	
FR 2035786	A	24-12-1970	FR 2035786 A5	24-12-1970
WO 0123405	A	05-04-2001	AU 7736300 A CA 2386095 A1 EP 1228083 A2 WO 0123405 A2	30-04-2001 05-04-2001 07-08-2002 05-04-2001
US 6117446	A	12-09-2000	AU 2513900 A CA 2359587 A1 EP 1150629 A1 WO 0042955 A1 US 6284263 B1 US 6221379 B1 US 6200593 B1 US 6241529 B1	07-08-2000 27-07-2000 07-11-2001 27-07-2000 04-09-2001 24-04-2001 13-03-2001 05-06-2001
WO 0074684	A	14-12-2000	AU 5181200 A EP 1187618 A1 JP 2003501390 T WO 0074684 A1	28-12-2000 20-03-2002 14-01-2003 14-12-2000